Cabel - In theory if Apabetalone proves promising for the treatment of AD/dementia the potential increase in our MC is not $15 billion, it hat only covers AD. It's $15 billion plus diabetic CVD value plus CKD value, in theory. That old cart keeps trying to get ahead of the horse though. First we have to pass the goal of the trial of statistically significant change in %RRR then the value of the sub studies value can be reflected. Whoever it was that posted last week that if we hit on all three in this trial it would be a unicorn hit the nail squarely on the head.

Here's to hoping for a unicorn!

tada